NLR & PLR and how they are linked to survival
NLR & PLR and how they are linked to survival
Pretreatment platelet-to-lymphocyte ratio (PLR) as a predictor of response to first-line platinum-based chemotherapy and prognosis for patients with non-small cell lung cancer
Our study shows that PLR maybe a potentially useful biomarker for predicting response to first-line chemotherapy and prognosis in NSCLC
Prognostic value of PLR in various cancers: a meta-analysis
The meta-analysis demonstrated that PLR could act as a significant biomarker in the prognosis of various cancers
Preoperative platelet lymphocyte ratio as an independent prognostic marker in ovarian cancer
We have shown for the first time that PLR is a novel independent prognostic marker in patients with ovarian cancer
Prognostic role of platelet to lymphocyte ratio in solid tumors: a systematic review and meta-analysis
A high PLR is associated with worse OS in various solid tumors. Further research of its regulation and relevance in daily practice is warranted. PLR is a readily available and inexpensive biomarker with independent prognostic value in solid tumors
Evaluation of the platelet-to-lymphocyte ratio as a prognostic indicator in a European cohort of patients with prostate cancer treated with radiotherapy.
Our findings indicate that the PLR may predict prognosis in patients with prostate cancer and may contribute to future individual risk assessment in them.
Predictive Value of the Platelet-To-Lymphocyte Ratio in Diagnosis of Prostate Cancer
Meta-analyses showed that in patients with PSA levels over 4 ng/ml, positive predictive value of PSA is only 25 percent. Therefore, novel markers which can both detect clinically significant prostate cancer, and also prevent unnecessary biopsies are needed. Relevant to this issue in addition to PSA density, velocity, and PCA3, various markers have been analyzed. In the present study, PLR were found to be the additional predictor of prostatic carcinoma.
Platelet to lymphocyte ratio as an independent prognostic indicator for prostate cancer patients receiving androgen deprivation therapy
PLR might play a significant role in the prognosis of PCa patients treated with ADT. Thus, we recommend adding PLR to traditional prognostic model to improve the predictive accuracy.
Patients were categorized in two groups using a cut-off point of 117.58 as calculated by the receiver-operating curve analysis
Lack of an Association between Neutrophil-to-Lymphocyte Ratio and PSA Failure of Prostate Cancer Patients Who Underwent Radical Prostatectomy
There was no association between NLR and biochemical failure after prostatectomy
Prognostic significance of neutrophil-to-lymphocyte ratio in prostate cancer: evidence from 16,266 patients
Our study demonstrated that elevated NLR predict poor OS and PFS/RFS in patients with PCa. Increased NLR showed consistent prognostic value in mCRPC patients and predict poor PFS/RFS in Asians, but not in Caucasians. The present findings could provide implications for clinical management of patients with PCa and further investigations involving large sample size and more ethnic backgrounds are needed.
Prognostic Role of Neutrophil-to-Lymphocyte Ratio in Prostate Cancer: A Systematic Review and Meta-analysis
Elevated NLR is a strong indicator of poorer prognosis of patients with mCRPC, whereas the NLR is not significantly associated with prognosis of patients with localized PCa. Therefore, NLR could be used in patients with mCRPC for risk stratification and decision making of individual treatment
Neutrophil-to-lymphocyte ratio predicts prostatic carcinoma in men undergoing needle biopsy
NLR is thus likely elevated in patients with prostate cancer. Accordingly, NLR, with or without combination with F/T PSA ratio, may function as a new biomarker to predict prostate cancer in men undergoing prostate needle biopsy
Baseline neutrophil–lymphocyte ratio (NLR) is associated with survival and response to treatment with second-line chemotherapy for advanced prostate cancer independent of baseline steroid use
NLR is a valid prognostic biomarker in CRPC and is associated with survival, PSA and RECIST responses in patients treated with second-line chemotherapy. Changes in NLR counts with treatment may indicate benefit. NLR prognostic value is independent of prior use of corticosteroids
Prognostic impact of preoperative neutrophil-to-lymphocyte ratio after radical prostatectomy in localized prostate cancer
This study shows that in patients with prostate cancer preoperative NLR is an independent prognostic factor for OS and CSS after a RP and suggests that a preoperative hematologic workup should be considered in the risk assessment of these patients
Neutrophil to lymphocyte ratio (NLR) impact on the survival and response duration of patients with metastatic castration resistant prostate cancer
The NLR was prognostic in this analysis, with a NLR > 5 at baseline associated to a worse OS. There was no relation between NLR and response duration, with similar PFS in both groups. There was a trend for better OS in patients with a NLR > 5 at baseline that converted to
Neutrophil-to-Lymphocyte Ratio Predicts PSA Response and Prognosis in Prostate Cancer: A Systematic Review and Meta-Analysis
Our results suggest that an elevated NLR might be employed as a prognostic marker of biochemical changes and prognosis to facilitate risk stratification and decision making for individual treatment of PCa patients. The potential mechanisms underlying these associations and future research directions are also discussed
Neutrophil count is associated with survival in localized prostate cancer
Neutrophil count, as a possible marker of systemic inflammation, appear to be an independent prognostic factor for overall mortality in localized prostate cancer. A validation cohort is needed to corroborate these results
Validation of the neutrophil‑to lymphocyte ratio as a prognostic factor in a cohort of European prostate cancer patients
The NLR seems to represent an independent prognostic marker and should be considered for future individual risk assessment in patients with prostate cancer.
Increased neutrophil-lymphocyte ratio is a poor prognostic factor in patients with primary operable and inoperable pancreatic cancer
Risk prediction for cancer-related end points using NLR does add independent prognostic information to other well-established prognostic factors in patients with PC, regardless of the undergoing therapeutic modality. Thus, the NLR should be considered for future individual risk assessment in patients with PC.
NLR vs PLR
Clinical significance of preoperative neutrophil-lymphocyte versus platelet-lymphocyte ratio in patients with operable colorectal cancer
The NLR and PLR were positively correlated (p < 0.001). Both the NLR and PLR were shown to be good prognostic biomarkers of overall survival (OS) (p=0.002 and p=0.001, respectively). The PLR was an independent prognostic factor of OS based on multivariate analysis (hazard ratio, 1.971; 95% confidence interval, 1.102-3.335; p=0.021)
Benign prostatic hyperplasia and prostate cancer differentiation via platelet to lymphocyte ratio
Effective malign and benign differentiation of prostate pathologies based on noninvasive inflammation biomarkers such NLR and PLR necessitate clinical studies with larger patient series